Filana Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Filana Therapeutics, Inc. (FLNA) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.46 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-05-07
- Filana Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$2.46M, a 556.88% decline year-over-year.
- Filana Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $2.96M.
- Filana Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $34.63M, a 19.37% decline year-over-year.
- Filana Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-03-31 was $538.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month |
|---|---|---|---|
| 2026-03-31 | -$2.46M 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $37.59M derived: sum of 2 quarters · filed 2025-11-12 | $38.13M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $34.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $35.17M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $538.00K 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | -$308.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $42.64M derived: sum of 2 quarters · filed 2025-11-12 | $41.67M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $42.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $41.98M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | -$970.00K 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | -$846.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.25M derived: sum of 2 quarters · filed 2024-11-07 | $5.82M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.66M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $4.57M 10-Q · filed 2024-05-10 | ||
| 2022-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $202.00K derived: sum of 2 quarters · filed 2023-11-07 | -$3.59M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.37M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | -$3.79M 10-Q · filed 2023-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |